Given the urgent need for designing a new antituberculosis vaccine conferring total protection on patients of all ages, following the line of research adopted by our institute, this work has identified Mycobacterium tuberculosis (Mtb) Rv3166c protein high-activity binding peptides (HABPs) which are able to inhibit bacterial invasion of U937 (monocyte-derived macrophages) and A549 (type II alveolar epithelial cells) cell lines. The presence and transcription of the rv3166c gene in the Mtb species complex was confirmed by polymerase chain reaction (PCR) and reverse transcriptase-PCR; Rv3166c expression was evaluated by western blot and cellular localisation confirmed by immunoelectron microscopy. Its presence was mainly determined on cell surface. Sixteen peptides covering its entire length were chemically synthesised and tested for their ability to bind to U937 and A549 cells. Two U937 HABPs were identified and three for A549, one of them being shared by both cell lines. The four HABPs found inhibited Mtb entry by 15.07 -94.06%. These results led us to including Rv3166c HABPs as candidates for further studies contributing towards the search for a multiepitope, chemically synthesised, subunit-based antituberculosis vaccine.
Introduction
Tuberculosis (TB) is one of the three infectious diseases having major public health importance worldwide, the others being malaria and acquired immunodeficiency syndrome (AIDS). The Mycobacterium tuberculosis (Mtb) bacillus is responsible for 8 800 000 new cases (139 cases per 100 000 inhabitants) and around 1.7 million deaths annually (WHO, 2009) . Although just 5 -10% of the people actually infected with tuberculosis develop it, a third of the world's population is infected with the bacillus thereby constituting an even bigger problem for people co-infected with AIDS (Corbett et al., 2003) . The appearance of multidrug-resistant tuberculosis strains (MDR-TB) and extremely drug-resistant tuberculosis strains (XDR-TB) in different geographical areas (Iseman, 1999) must be added to this problem.
Even though there is an anti-TB vaccine (the Mycobacterium bovis bacillus Calmette-Guérin, BCG, attenuated strain), meta-analysis studies have demonstrated that it has high variability (0 -80%) and that it is also ineffective in adults (Fine and Vynnycky, 1998; Black et al., 2003; Fine, 2005) . Although BCG generates a circulating population of cells in response to Mycobacterium, these are not efficient enough to prevent rapid bacterial growth in the lungs (Cooper, 2009) , meaning that a more effective vaccine must be designed which confers complete protection against the disease. Global research has focused on finding new Mtb-specific antigens which could be used as an alternative for replacing or improving the BCG vaccine (Kaufmann et al., 2006; Changhong et al., 2009) .
The Mtb bacillus is a facultative intracellular pathogen; infection begins with its entry through the respiratory airways after aerosols have been inhaled from an individual having the active disease. The bacillus then becomes located in the pulmonary alveoli where it invades epithelial cells and becomes phagocytosed by macrophages, representing the first step in the pathogen -host interaction (Raja, 2004) . It has been demonstrated that the bacillus is able to invade other nonphagocytic cells, such as HeLa cells and fibroblasts (Garcia-Perez et al., 2003) .
Different molecules must be expressed in the host-pathogen interaction for pathogenesis to occur, mainly those exposed on the bacillus surface since they perform enzymatic and signal transduction functions, or could be acting as receptors (Sigler and Hofer, 1997; Asselineau et al., 2002; Nigou et al., 2003; Malen et al., 2007) .
The rv3166c gene encodes a transmembrane protein containing three hundred and nineteen 33.4 kDa molecular weight amino acids. It appears as a conserved hypothetical protein in the Tuberculist server (http://genolist.pasteur.fr/ TubercuList/).
The Rv3166c protein may have molecular functions according to the ProKnow annotation function server such as zinc ion binding and catalytic activity, as well as biological functions such as electron transport, carbohydrate metabolism and transcription regulation (http://www.doe-mbi.ucla. edu/TB/PUBLIC/qs/qsearch.php?orf=Rv3166c).
It has been reported that the Mtb rv3166c gene forms part of the group of genes which are suppressed when the bacillus is treated with isoniazid (INH) (Fu, 2006) . It has also been found that the SigL regulatory sigma factor helps rv3166 gene expression, among other genes which may be involved in important cell envelope processes (Dainese et al., 2006) . The Rv3166c protein was chosen for further research to build on previously obtained results Vizcaino et al., 2010) . The rv3166c gene's presence and transcription was evaluated in Mtb H37Rv and Mtb H37Ra strains using polymerase chain reaction (PCR) and reverse transcriptase-PCR (RT-PCR) assays. Rv3166c expression and subcellular localisation was experimentally verified by western blot and immunoelectron microscopy, respectively. The Rv3166c protein was synthesised in 20-mer long, nonoverlapped peptides which were analysed using a robust and highly specific methodology (widely used in Plasmodium falciparum studies in our institute) (Garcia et al., 2006; Patarroyo and Patarroyo, 2008; Rodriguez et al., 2008) to identify high-activity binding peptides (HABPs). These peptides' ability to inhibit mycobacterial entry into macrophages derived from monocytes (U937) and alveolar type II epithelial cells (A549) was also evaluated. Taking into account the results obtained for Rv3166c, then some of the Rv3166c-HABPs mentioned below may be considered in future studies regarding their immunomodulatory nature and become included in designing a multiepitope, subunit-based, chemically synthesised vaccine against TB.
Results

rv3166 gene presence and transcription
The Mtb Rv3166c protein sequence was obtained from the Tuberculist Webserver database (http://genolist.pasteur.fr/ TubercuList/) and used as the query sequence for BLASTp analysis (http://blast.ncbi.nlm.nih.gov/Blast.cgi). This analysis revealed 100% identity with M.bovis BCG BCG_319c and Mycobacterium leprae MLCB1779.35c hypothetical proteins, 98% with a conserved Mycobacterium parascrofulaceum hypothetical protein and 97% with Mycobacterium kansasii MkanA1_10062 and Mycobacterium avium MAV_4054 hypothetical proteins.
PCR experiments with mycobacterial gDNA confirmed the presence of the rv3166 gene in both strains tested. The 360-and 566-bp amplification fragments were obtained for rpoB and rv3166 genes in Mtb H37Rv and H37Ra, respectively (Fig. 1A) .
The rpoB constitutive gene amplification by Plus synthesis cDNA kit (EasyScript) was used as control for transcription assays for each mycobacterial strain; the absence of product in RT control synthesis confirmed that there was no contamination with gDNA. The 566-bp amplification fragment observed in Mtb H37Rv and H37Ra plus synthesis cDNA indicated that the rv3166 gene was being transcribed in both strains in 7H9 culture medium conditions (Fig. 1B) .
Rv3166c protein recognition
Sera obtained from rabbits inoculated with polymer peptides were used in western blot (Fig. 2) against Mtb H37Rv sonicate and subcellular fractions (wall, membrane and cytosol). Sera were pre-adsorbed on columns with Escherichia coli and Mycobacterium smegmatis lysates and synthetic P.falciparum 66 (SPf66) vaccine to eliminate cross-reactivity against bacterial, mycobacterial and polymerisation antigens.
Pre-immune serum did not recognise proteins from Mtb H37Rv total sonicate (Fig. 2, lane 1) ; the serum obtained by inoculating peptide 16 298 recognised an intense 33 kDa band in both total sonicate and mycobacterial wall, cytosol and membrane fractions. A 10 kDa band was also recognised in cell wall and cytosol fractions, but with lower intensity (Fig. 2) .
Rv3166c protein localisation was corroborated by the immunoelectron microscopy (IEM) technique. Figure 3 shows that Rv3166c is a surface protein due to the presence of more colloidal gold particles on Mtb H37Rv surface than inside the bacillus.
Rv3166c peptides' binding activity
Taking Rv3166c localisation into account, 20 amino acid nonoverlapped peptides covering the whole protein sequence were synthesised. Figure 4 
Mycobacterial entry inhibition
Inhibition of mycobacterial entry due to HABP binding is shown in Fig. 5 . Peptide 16 295 only inhibited this by 6.38% when it was used at the highest concentration evaluated in the assay (100 mM). The three remaining peptides had concentration-dependent inhibition, thereby discarding a toxic peptide effect on these cells.
Peptide 16 296 inhibited mycobacterial entry to A549 cells by 15.07 and 46.79% at 50 and 100 mM peptide concentration, respectively. On the contrary, 16 298 was able to inhibit invasion of A549 cells, even at very low peptide concentrations such as 5 mM (46.42%), reaching 55.77% entry inhibition at 50 mM and 65.36% at 100 mM. The 10 mM cytochalasin control inhibited mycobacterial entry by 89.99%; this reagent is known to be an actin polymerisation inhibitor. Otherwise, anti-16 298 serum was used as inhibitor in assays regarding mycobacterial invasion of A549 cells. The serum (1 : 100) was able to inhibit around 29% of mycobacterial entry to host cells. Pre-immune and anti-16 300 Rv3166c peptides inhibit mycobacterial entry to cells sera were used as control as they did not inhibit mycobacterial entry.
In the assay regarding inhibition of Mtb H37Rv entry to U937 cells, the cytochalasin control prevented inhibition by 93.67% at 10 mM concentration. Peptide 16 287 progressively inhibited entry when peptide concentration was increased: 37.37% inhibition at 5 mM, 52.81% at 50 mM and 58.68% at 100 mM. By contrast, 16 296 had very high inhibition percentages (92.03-94.06%) at all concentrations used; this could have suggested a toxic effect on the cells, even though no damage was observed in U937 cell morphology during this assay. This peptide thus presented a different effect compared with mycobacterial entry inhibition regarding each cell line.
Scrambled HABPs (having the same amino acid composition but different sequence) were synthesised and their inhibitory activities were also determined by following the same methodology. Scrambled peptide 38 270 (RALGGPAG PMLDAYALHLLAD), 16 287 analogue and 38 271 (SSRE YPLASGEAASEAAILRP) 16 296 analogue had ,10% inhibitory effect at all concentrations tested.
HAPBs' structural elements Figure 6 shows that peptides 16 287 and 16 296 had a-helix structural elements, characterised by a 212 nm maximum and 207 and 222 nm minima, whereas peptides 16 295 and 16 298 had a random coil configuration, characterised by a 198 nm minimum and 212 nm maximum. These results agreed with the secondary structure prediction given by the self-optimised prediction method with alignment (SOPMA) for the same peptides (http://npsa-pbil.ibcp.fr/NPSA/npsa_ sopma.html). 
Discussion
Despite the efforts made at preventing and controlling tuberculosis, this disease continues to cause millions of deaths annually. In spite of the BCG vaccine being available and drug treatments producing variable protection, these have not been consolidated as effective methods aimed at preventing the disease. This has shown how imperative it is to have a new vaccine conferring total protection against tuberculosis. A methodology for developing a new vaccine has thus been implemented in our institute which has been based on chemically synthesised Mtb surface protein peptides having specific U937 macrophage and alveolar epithelial A549 cell binding activity (HABPs), as well as being able to inhibit pathogen entry to such cells (Forero et al., 2005; Garcia et al., 2005; Vera-Bravo et al., 2005; Plaza et al., 2007; Chapeton-Montes et al., 2008; Patarroyo et al., 2008a, b; Cifuentes et al., 2010; Cáceres et al., 2011; Ocampo et al., 2011) .
As Mtb entry to host cells is mediated by the bacillus' surface interacting with cell membrane receptors, our studies have been focused on this pathogen's surface proteins. Most of these proteins' functions are not known, nor are their possible role in bacterial invasion of host cells or the role they play in bacillus survival within the host cell. This study has been focused on the Rv3166c surface protein which has been classified as a membrane protein according to predictions made by using bioinformatic tools. Comparative analyses have revealed Rv3166c protein homologues in M.leprae, M.parascrofulaceum, M.kansasii and M.avium mycobacterial strains outside the Mtb complex (MTC); these species are also disease-causing agents in both humans and other mammals. Rv3166c's high percentage of identity with other pathogenic species different to Mtb thus indicates this protein's possible role in virulence and infection. It has been possible to determine the presence of the gene encoding the Rv3166c protein in Mtb H37Rv experimentally using the laboratory reference strain.
The TMHMM v. 2.0 (http://www.cbs.dtu.dk/services/ TMHMM/) tool led to determining the presence of transmembrane regions; four transmembrane helices were predicted in the following amino acids: i12 -34o, o49 -71i, i101 -123o and o161 -183i (i/o denotes inside or outside). The first helix was a possible signal peptide according to TMHMM. However, it was found that Rv3166c did not present a signal peptide when using SignalP and SecretomeP tools . This suggested that the protein was being secreted via the general export pathway (Gomez et al., 2000) .
Protein expression was assessed once rv3166c gene transcription had been confirmed in Mtb H37Rv. The serum obtained by inoculating polymer peptide 16 298 recognised an intense 33 kDa band; taking into account that the calculated molecular weight for Rv3166c is around 33.4 kDa, then it could be suggested that the serum contained specific antibodies against the protein of interest. The low molecular weight and weak 10 kDa band could have been due to a protein cleavage product being recognised in the cytoplasm; homology analysis discarded the possibility that such recognition was due to a cross-reaction with another mycobacterial antigen. These results indicated that the protein was being effectively expressed in the virulent Mtb strain and bioinformatics predictions were corroborated, placing Rv3166c within the mycobacterial envelope. IEM assays corroborated this protein's location on the mycobacterial surface thereby leading to the assumption that it might interact with host cell surface receptors. Established Rv3166c annotation as a secreted protein (http://www.doe-mbi.ucla.edu/TB/ PUBLIC/qs/qsearch.php?orf=Rv3166c) disagrees with the experimental results reported here, which demonstrated its localisation on the mycobacterial envelope.
It has been found that Mtb surface proteins interact with different receptors on host cell surface to mediate invasion by the bacillus; some of these would be mannose receptors, Toll-like receptors, scavenger receptors, surfactant protein A and D receptors and complement receptors 1, 3 and 4 (Ernst, 1998; Rooyakkers and Stokes, 2005) . Taking the specific interaction between mycobacterial protein sequences and the host cell into account, the HABPs' ability to bind to A549 and U937 cells was determined to establish whether peptides binding to target cells were able to inhibit Mtb H37Rv entry to these cells. Peptide 16 287 presented high specific U937 binding activity at the N-terminal and significant inhibition of mycobacterial entry to these cells while 16 295 and 16 298 bound specifically to A549 cells at the C-terminal, even though 16 295 had very low inhibition which is why it was assumed that this sequence's specific interaction with A549 epithelial cells was not relevant for Mtb entry. It is interesting that 16 296 bound to both cell lines with high activity and inhibited mycobacterial entry to A549 cells regardless of concentration, whereas it had a highly inhibitory effect on mycobacterial entry to U937 cells at the concentrations assayed here.
Inhibition assays involving U937 cells with scrambled HABPs (i.e. peptides having the same amino acid composition but different sequence) demonstrated that HABP entry inhibition depended exclusively on their amino acid sequence and thus on their structural configuration since their activity became reduced when their sequences became altered.
Bearing in mind the relationship between peptide structure and function as an immunogen, structural element content had to be determined by circular dichroism (CD) analysis for all Rv3166c HABPs. The results with the corresponding deconvolution using SELCON, CONTINLL and CDSSTR software (Sreerama and Woody, 2000) showed b-turn and a-helix features as being these HABPs' main structural characteristics. A relationship could not be established between each HABP's structure and its binding or inhibitory activity.
The presence and transcription of the Rv3166c protein-encoding gene has thus been shown experimentally in Mtb strains. This protein was expressed in normal culture conditions and was mainly localised on mycobacterial surface. Only 4 of the 16 peptides constituting the protein sequence had high specific binding ability (HABPs) regarding infection of target cells (macrophages and alveolar epithelial cells). The structural elements found for these peptides fit the predictions made by bioinformatic tools. Peptides 16 287, 16 296 and 16 298 were of special interest because they significantly inhibited mycobacterial entry to target cells. These peptides will be used in further studies for establishing their immunomodulating potential, taking into account that our approach is based on the search for protein fragments which are involved in mycobacterial -target cell interaction.
Rv3166c peptides inhibit mycobacterial entry to cells
An HABP's antiserum inhibitory effect on invasion could be associated with Rv3166c location on the surface involved in target cell invasion, thereby confirming the results of protein immunolocalisation. Likewise, treating Mtb H37Rv with proteinase K (nonspecific serin protease), removing surface proteins, has completely inhibited mycobacterial entry to epithelial cells and macrophages in in vitro assays, thereby showing the importance of mycobacterial surface protein components in an interaction with (infection) target cells. The principles underlying the proposed methodology have been based on identifying HABPs from Mtb proteins involved in mycobacterial entry to the host cell for inducing an immune response which may be able to block their binding to the host cell. This is why HABPs which are able to inhibit mycobacterial entry to macrophages and epithelial cells in vitro have been of such special interest as they will be tested in assays using animal models for evaluating their protection-inducing potential against Mtb infection.
In our experience concerning P.falciparum, sequences specifically binding to target cells and which can block invasion could be used as templates for designing peptides which can immunomodulate a protective response against the disease. An immune response triggered against mycobacterial high specific binding sequences could prevent the invasion of target cells, either during a first encounter with the bacillus or during the reactivation of a latent infection.
Materials and methods
Chromosomal DNA extraction and PCR amplification
The presence and transcription of the rv3166c gene was assessed in the Mtb H37Rv (ATCC 27 294) and H37Ra (ATCC 25 177) strains. Genomic DNA was extracted using an Ultra Clean Microbial DNA Isolation Kit (MO Biolab), following the manufacturer's recommendations. Extracted DNA was suspended and kept in 1X TE buffer.
PCR amplifications were performed in a thermocycler (Perkin Elmer Gene Amp PCR system 9600), 100 ng of genomic DNA from the different Mycobacterium strains being incubated with a PCR mixture (1.5 mM MgCl 2 , 1 mM dNTPs, 1 mM of each oligonucleotide primer and 1.25 U BioTaq DNA polymerase (Bioline), 1Â Taq polymerase reaction buffer). The PCR conditions were as follows: an initial 5-min denaturing stage at 948C followed by 35 cycles consisting of: 30 s at 588C, 30 s at 728C and 15 s at 948C. A final extension cycle lasted 5 min at 728C.
Extracted DNA quality was assessed by amplifying a 360 base pair (bp) fragment from the rpoB gene (encoding the RNA polymerase B-subunit) using sense (5 0 -TCAAGGAG AAGCGCTACGA-3 0 ) and antisense (5 0 -GGATGTTGATCA GGGTCTGC-3 0 ) primers. The gene encoding Rv3166c in the Mtb H37Rv strain was analysed to design a specific primer set to verify the presence and transcription of this gene in in vitro culture conditions. The designed primers' sequences were: rv3166c-sense: 5 0 -GCTGCTGATTGCGA TACTG-3 0 and rv3166c-antisense: 5 0 -CCTCACGGTGCTC CTCG-3 0 , which amplified a 566 bp fragment. DNase-and RNase-free water was used as a negative PCR control for all reactions. All amplifications were visualised on 1.5% agarose gel stained with SYBR Safe (Invitrogen, Carlsbad, CA, USA).
RNA extraction and RT-PCR. Total RNA was isolated from the bacterial pellet by homogenisation in 1 ml TRIZOL reagent (Invitrogen) following the manufacturer's suggested protocol, then 10 ml of the sample were treated with amplification grade deoxyribonuclease I (Invitrogen). Complementary DNA (cDNA) synthesis was carried out using SuperScript III reverse transcriptase (Invitrogen) and random hexamers following the manufacturer's recommendations. A negative synthesis control replacing the SuperScript III enzyme with diethylpyrocarbonate-treated water was also included for each sample. Two micro litre cDNA were used as template for PCR amplification following the conditions previously described for DNA. The rpoB gene was used as positive transcription control (Lee et al., 2000) .
Peptide synthesis and radiolabelling
Sixteen 20-mer-long non-overlapped peptides were synthesised, covering the entire Rv3166c protein sequence. Peptides were synthesised in solid phase (t-Boc technique). Peptides were then purified by reversed phase-high-performance liquid chromatography and characterised by matrixassisted laser desorption/ionization-time of flight mass spectrometry. A Tyr residue was added at the C-terminus of those peptides lacking it to facilitate I 125 radiolabelling (Garcia et al., 2004; Rodriguez, et al., 2008; Ocampo et al., 2011) . Purified peptides (2 nmol) were radiolabelled with 5 ml NaI 125 (100 mCi/ml, ICN) and 0.3 mmol of chloramine-T. After incubation for 15 min, the reaction was stopped with 0.18 mmol of sodium metabisulphite. The radiolabelled peptide was passed through a Sephadex G-10 column (Pharmacia) to separate it from the reaction subproducts.
Cell culture
The A549 (ATCC CLL-185) and U937 (ATCC CRL-2367) cell lines were kept in Roswell Park Memorial Institute (RPMI) 1640 medium culture supplemented with 10% fetal bovine serum (FBS) at 378C and 5% CO 2 . These two adherent cell lines were detached using 0.6% trypsin and 0.2% ethylenediaminetetraacetic acid. Cells were spun at 500 g for 5 min and suspended in RPMI 1640 medium without serum.
Binding assays
A highly specific, sensitive and robust receptor-ligand-type binding assay was based on previous studies with U937 human alveolar macrophages and alveolar epithelial A549 cells (Forero et al., 2005; Garcia et al., 2005; Vera-Bravo et al., 2005; Plaza et al., 2007; Cifuentes et al., 2010; Cáceres et al., 2011; Ocampo et al., 2011) . 1.5 Â 10 6 cells were incubated with different radiolabelled peptide concentrations (0 -950 nM) in the presence or absence of the same nonradiolabelled peptide (40 mM) for 90 min at 48C. An aliquot of this mixture was passed through a 60 : 40 dioctylphthalate-dibutylphthalate cushion (1015 g/ml) and spun at 4500 g for 3 min. A gamma counter was used for quantifying cell-associated radioactivity. All assays were performed in triplicate. Peptides having .1% specific binding were considered to be HABPs, in line with previous studies performed in our laboratory (Forero et al., 2005; CD assays. Rv3166c HABPs were analysed by CD to determine possible secondary structure elements present in their sequences and to determine whether there were a structurefunction correlation. CD spectra were registered at 208C on a Jasco J-810 spectropolarimeter at wavelengths ranging from 260 to 190 nm, in 1-cm cuvettes (Provencher and Glockner, 1981; Greenfield, 1999) . Peptides were dissolved at 0.1 mM concentration in pure water or 30% (v/v) trifluoroethanol/ water. Each spectrum was obtained by averaging three readings taken at 20 nm/min, using 1 nm spectra bandwidth, corrected for base deviation. The results were expressed as mean residue ellipticity [É], its units being degreesÂcm 2 Â dmol, according to [É] ¼ Él/(100lcn), where Él is measured ellipticity, l is the optical path length, c the peptide concentration and n the number of amino acid residues in the peptide sequence (Sreerama et al., 1999) .
Rabbit immunisation and western blot
Peptide sequences chosen for immunising rabbits were selected based on a Rv3166c sequence analysis, using BepiPred 1. The Mtb H37Rv proteins from total sonicate and cell fractions (wall, membrane, cytosol and filtrate) were separated in a sodium dedocyl sulphate-polyacrylamide gel electrophoresis discontinuous system, using a 10-20% polyacrylamide gradient. A total of 1 mg/ml from each fraction and sonicate were loaded onto each gel. Gels were transferred to nitrocellulose membranes using the semi-dry blotting technique (Kyhse-Andersen, 1984) and blocked (blocking solution: 1% TBS-Tween and 5% milk). The membranes were incubated for 1 h with a 1 : 100 dilution of each rabbit serum. Following five 1% TBS-Tween washes they were incubated for 1 h with a 1 : 5000 dilution of alkaline phosphatase conjugated with antirabbit IgG antibody. The reactions were revealed with nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl-phosphate.
Immunoelectron microscopy
The Rv3166c protein's subcellular localisation was determined by Hitachi Hu-12A transmission electronic microscope. Fine slices (400 nm) of mycobacteria immersed in London resin white resin were prepared. The same immunoblot serum was used as primary antibody and colloidal gold particle-coupled antirabbit IgG was used as secondary antibody. Six per centuranyl acetate was added to provide the samples with contrast (Plaza et al., 2007; Cifuentes et al., 2010; Cáceres et al., 2011; Ocampo et al., 2011) .
Invasion inhibition assays
The assay for determining HABPs' role in mycobacterial entry has been described previously (Bermudez and Goodman, 1996; Chapeton-Montes et al., 2008; . Mycobacterium tuberculosis H37Rv was cultured in a Middlebrook 7H9 medium for 12 days (mid-log phase), then harvested and suspended in 1Â phosphate buffered saline. Bacteria were labelled with 2 ml 20Â SYBR Safe.
A549 and U937 cells were loaded into six-well plates with FBS-supplemented RPMI 1640 medium (Gibco) and incubated at 378C in 5% CO 2 overnight. Different peptide concentrations of 400 ml (5, 50 and 100 mM) were added to each well and incubated at 378C for 1 h. Each treatment was performed in triplicate with its respective negative control. Cells were incubated with RPMI 1640 medium as invasion control and cytochalasin D (10 mM) was used as inhibition control. About 1 Â 10 9 Mtb bacilli, suspended in 200 ml RPMI medium without antibiotics, were loaded per well. Multiplicity of infection (MIO) was 1 : 1000. Plates were incubated at 378C overnight. This was followed by three washes with Hank's buffered salt solution to remove extracellular bacteria. The cell monolayer was detached and infected cells were fixed with 400 ml 2% paraformaldehyde at 48C for 1 h. Before the samples were read on the cytometer, cells were incubated for 5 min with 200 ml 0.3% methylene blue to eliminate autofluorescence. The samples were analysed on a FACScan cytometer (Becton Dickinson) equipped with a 488-nm argon laser. Data were acquired using Cellquest software (Becton Dickinson) and analysed by using FCS Express V3 cytometry software; 5000 events were read for each sample (Chapeton-Montes et al., 2008) . The data were statistically analysed using Student's t-test.
